Immix Biopharma (IMMX) Change in Accured Expenses (2021 - 2026)

Immix Biopharma (IMMX) has 6 years of Change in Accured Expenses data on file, last reported at $432207.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 67.06% year-over-year to $432207.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 56.11% YoY), and the FY2025 full-year result was $1.0 million, down 76.66% from the prior year.
• Change in Accured Expenses advanced to $432207.0 in Q1 2026, from -$790864.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.3 million in Q4 2024 to a low of -$1.8 million in Q2 2024.
• A 5-year average of $487432.9 and a median of $451957.0 in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 61850.0% in 2023 and plunged 292.53% in 2024, its largest moves.
• Tracing IMMX's Change in Accured Expenses over 5 years: stood at -$516044.0 in 2022, then jumped by 265.53% to $854219.0 in 2023, then surged by 167.04% to $2.3 million in 2024, then plunged by 134.67% to -$790864.0 in 2025, then soared by 154.65% to $432207.0 in 2026.
• Business Quant data shows IMMX's Change in Accured Expenses at $432207.0 in Q1 2026, -$790864.0 in Q4 2025, and $1.0 million in Q3 2025.